New test may expand olaparib benefits to more ovarian cancer patients
NCT ID NCT04780945
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new lab method (RAD51 assay) to see if it could identify ovarian cancer patients whose tumors are vulnerable to the drug olaparib, even if they don't have BRCA gene mutations. The goal was to find a larger group of patients who might benefit from this treatment. The study was terminated early, but it aimed to improve how doctors select treatments for recurrent ovarian cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRCA1 MUTATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Erasmus Medical Center
Rotterdam, Netherlands
-
Leiden University Medical Center
Leiden, 2300RC, Netherlands
-
University Medical Center Groningen
Groningen, Netherlands
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Ovarian tumor genes may reveal who needs stronger treatment
- New hope for tough pancreatic cancer: targeted drug trial launches
- Hormone boost plus chemo aims to shrink hard-to-treat prostate cancer
- Could a 'Baby Dose' of hormone pills prevent breast cancer?
- Toolkit aims to break the silence around inherited cancer genes
- New drug shows promise for Hard-to-Treat cancers with specific gene flaw